Bridgefront Capital LLC Makes New Investment in Novo Nordisk A/S (NYSE:NVO)

Bridgefront Capital LLC acquired a new position in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 3,963 shares of the company's stock, valued at approximately $341,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Center for Financial Planning Inc. boosted its position in shares of Novo Nordisk A/S by 72.4% during the 4th quarter. Center for Financial Planning Inc. now owns 293 shares of the company's stock valued at $25,000 after acquiring an additional 123 shares during the last quarter. Strategic Investment Solutions Inc. IL lifted its position in Novo Nordisk A/S by 2,727.3% during the fourth quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company's stock valued at $27,000 after purchasing an additional 300 shares during the last quarter. Transce3nd LLC bought a new position in shares of Novo Nordisk A/S in the 4th quarter worth $33,000. Kelly Lawrence W & Associates Inc. CA purchased a new stake in shares of Novo Nordisk A/S during the 4th quarter valued at $39,000. Finally, Albion Financial Group UT lifted its holdings in shares of Novo Nordisk A/S by 121.4% during the 4th quarter. Albion Financial Group UT now owns 507 shares of the company's stock worth $44,000 after acquiring an additional 278 shares during the last quarter. 11.54% of the stock is currently owned by institutional investors.

Novo Nordisk A/S Trading Up 1.4 %

Shares of NYSE:NVO traded up $0.90 during midday trading on Friday, hitting $65.75. 13,058,660 shares of the stock traded hands, compared to its average volume of 6,374,098. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62. The business's 50 day moving average is $69.21 and its two-hundred day moving average is $86.23. The stock has a market capitalization of $295.06 billion, a PE ratio of 19.98, a P/E/G ratio of 0.90 and a beta of 0.65. Novo Nordisk A/S has a one year low of $57.00 and a one year high of $148.15.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported $0.92 EPS for the quarter, meeting analysts' consensus estimates of $0.92. The business had revenue of $11.87 billion during the quarter, compared to analyst estimates of $79.17 billion. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. As a group, research analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms have weighed in on NVO. Hsbc Global Res upgraded Novo Nordisk A/S to a "strong-buy" rating in a research report on Monday, April 28th. Guggenheim downgraded Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research report on Thursday, April 17th. Morgan Stanley began coverage on shares of Novo Nordisk A/S in a research report on Wednesday, February 12th. They set an "equal weight" rating on the stock. StockNews.com upgraded shares of Novo Nordisk A/S from a "buy" rating to a "strong-buy" rating in a report on Friday, April 25th. Finally, BMO Capital Markets reaffirmed a "market perform" rating and set a $64.00 target price (down previously from $105.00) on shares of Novo Nordisk A/S in a report on Thursday, April 17th. Two analysts have rated the stock with a sell rating, five have issued a hold rating, five have issued a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $135.00.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.